Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 10Gastrointestinal 5Head & Neck 4Dermatologic 4Other solid neoplasm 3Lymphoid 2Genitourinary 2Breast 2Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Lymphoma 725Lymphoma, Non-Hodgkin 659Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Lymphoma, Mantle-Cell 345Burkitt Lymphoma 306Leukemia 304Leukemia, Myeloid, Acute 298Hodgkin Disease 294Lymphoma, B-Cell 281Lymphoma, B-Cell, Marginal Zone 267Recurrence 246Multiple Myeloma 205Neoplasms 200Myelodysplastic Syndromes 171Lymphoma, T-Cell, Cutaneous 171Lymphoma, Large-Cell, Immunoblastic 160Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Waldenstrom Macroglobulinemia 146Lymphoma, Large-Cell, Anaplastic 142Mycosis Fungoides 132Sezary Syndrome 119Immunoblastic Lymphadenopathy 108Blast Crisis 92Hematologic Neoplasms 91Lymphoma, T-Cell, Peripheral 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Lymphoma, T-Cell 82

Interventions

pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Lymphoid × Clear all
NCT03010176 2025-10-29

MK-1454-001

Merck Sharp & Dohme LLC

Phase 1 Completed
156 enrolled 20 charts
Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04317066 2025-04-06

KEYNOTE-A33

Merck Sharp & Dohme LLC

Phase 1 Completed
7 enrolled 13 charts
Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡